Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dienogest

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dienogest
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Menorrhagia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pregnadien derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dienogest in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dienogest with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants

    NCT04495855 · start 2020-10-28

    Registered record
    Registry ID
    NCT04495855
    Conditions
    Endometriosis
    Interventions
    Dienogest (Visanne,BAY86_5258)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-10-28
    Completion
    2022-12-23
    Enrolment
    968

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest (Visanne,BAY86_5258)
    PhaseNot recorded
    Registry statusCompleted

  • Bioavailability of Dienogest 2.0 mg With Regards to Reference Product

    NCT04230083 · start 2019-12-07

    Registered record
    Registry ID
    NCT04230083
    Conditions
    Bioequivalence
    Interventions
    Dienogest 2.0 mg Test Drug; Dienogest 2.0 mg Reference Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-07
    Completion
    2019-12-24
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionDienogest 2.0 mg Test Drug; Dienogest 2.0 mg Reference Product
    PhasePhase 1
    Registry statusCompleted

  • Dienogest for Treatment of Adenomyotic Uteri

    NCT03890042 · start 2019-03-01

    Registered record
    Registry ID
    NCT03890042
    Conditions
    Adenomyosis
    Interventions
    Dienogest group; Gestodene-Ethinyl Estradiol; Ultrasound; visual analogue scale
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-01
    Completion
    2020-08-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis
    InterventionDienogest group; Gestodene-Ethinyl Estradiol; Ultrasound; visual analogue scale
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma

    NCT03789123 · start 2019-01-01

    Registered record
    Registry ID
    NCT03789123
    Conditions
    Ovarian Reserve
    Interventions
    Estradiol valerate/dienogest
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2019-12-01
    Enrolment
    710

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Reserve
    InterventionEstradiol valerate/dienogest
    PhasePhase 4
    Registry statusUnknown

  • A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment

    NCT03751800 · start 2018-12-12

    Registered record
    Registry ID
    NCT03751800
    Conditions
    Menorrhagia
    Interventions
    Chronic hormonal treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-12
    Completion
    2021-05-18
    Enrolment
    422

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenorrhagia
    InterventionChronic hormonal treatment
    PhaseNot recorded
    Registry statusCompleted

  • Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis

    NCT03654144 · start 2018-11

    Registered record
    Registry ID
    NCT03654144
    Conditions
    Adenomyosis
    Interventions
    Dienogest; Combined Oral Contraceptive
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-11
    Completion
    2020-03
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis
    InterventionDienogest; Combined Oral Contraceptive
    PhasePhase 4
    Registry statusUnknown

  • Dienogest in Perimenopausal Women With Adenomyosis

    NCT05751876 · start 2018-09-01

    Registered record
    Registry ID
    NCT05751876
    Conditions
    Adenomyosis; Medication Adherence
    Interventions
    Dienogest
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2021-12-31
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis; Medication Adherence
    InterventionDienogest
    PhaseNot recorded
    Registry statusCompleted

  • Estrogen Replacement in Anorexia Nervosa

    NCT03172533 · start 2016-03-15

    Registered record
    Registry ID
    NCT03172533
    Conditions
    Anorexia Nervosa
    Interventions
    ethinyl estradiol 0.03mg and dienogest 2 mg (combination); Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-03-15
    Completion
    2019-01-15
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa
    Interventionethinyl estradiol 0.03mg and dienogest 2 mg (combination); Placebo oral capsule
    PhasePhase 2
    Registry statusTerminated

  • Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas

    NCT02599077 · start 2015-11

    Registered record
    Registry ID
    NCT02599077
    Conditions
    Endometriosis
    Interventions
    Dienogest; Levonorgestrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Suspended
    Start
    2015-11
    Completion
    2018-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest; Levonorgestrel
    PhasePhase 2 / Phase 3
    Registry statusSuspended

  • To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis

    NCT02425462 · start 2015-04-28

    Registered record
    Registry ID
    NCT02425462
    Conditions
    Endometriosis
    Interventions
    Dienogest (Visanne, BAY86-5258)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-04-28
    Completion
    2018-12-14
    Enrolment
    895

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest (Visanne, BAY86-5258)
    PhaseNot recorded
    Registry statusCompleted

  • Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome

    NCT02427334 · start 2015-04

    Registered record
    Registry ID
    NCT02427334
    Conditions
    Premenstrual Syndrome
    Interventions
    Dienogest; Fluoxetine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2021-12
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Syndrome
    InterventionDienogest; Fluoxetine; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy

    NCT01602770 · start 2015-02-06

    Registered record
    Registry ID
    NCT01602770
    Conditions
    Contraception
    Interventions
    EV/DNG (Qlaira, BAY86-5027)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-02-06
    Completion
    2017-10-31
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEV/DNG (Qlaira, BAY86-5027)
    PhaseNot recorded
    Registry statusCompleted

  • Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery

    NCT02385448 · start 2015-02

    Registered record
    Registry ID
    NCT02385448
    Conditions
    Endometriosis
    Interventions
    Dienogest; Microgynon
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-02
    Completion
    2019-02
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest; Microgynon
    PhasePhase 4
    Registry statusUnknown

  • Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest

    NCT02575248 · start 2014-10

    Registered record
    Registry ID
    NCT02575248
    Conditions
    Infertility
    Interventions
    Dienogest 2mg; Clomiphene citrate 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2017-07
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionDienogest 2mg; Clomiphene citrate 5 mg
    PhasePhase 4
    Registry statusUnknown

  • Regulatory Post Marketing Surveillance Study in Korea

    NCT01788722 · start 2013-07-19

    Registered record
    Registry ID
    NCT01788722
    Conditions
    Endometriosis
    Interventions
    Dienogest (Visanne, BAY86-5258)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-07-19
    Completion
    2017-08-11
    Enrolment
    3,223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionDienogest (Visanne, BAY86-5258)
    PhaseNot recorded
    Registry statusCompleted